All For One by Beahler, John
A cancer patient tells her story, as an 
unprecedented array of researchers across 
campus is developing the latest prospects 
for surviving the disease. 
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ANNE \VIlLLER IS LUCKY. A ROUTINE mammogram found the small 
tumor grow ing in her breast 
before it had time to spread . She ami her 
doctors know that now. hut aftcr her first 
surgery ill January they weren't as .sure. 
That's because breast cancer can iuva(le 
other organs if it isn't caught early 
enough. As a precaution, surgeons rou-
tinely remove lymph nodes under the arm, 
the spot where breast cancer is most 
likel)' to spread. 
Removing those n()(les gives cancer 
patients a safety margin, but it also can 
causesc\"Cre problem.r-hurning pain , 
numi)lless, swell ing an(l chronic infections. 
Many womellllced physical therapy after 
thesurgcr), to restore loss of motion. "My 
canei"'r was eaught carl)' and was very 
small , so t he chnnces of it being in the 
lymph 1l()(les were slight," Weller says ... , 
jU5t couldn't sec an)' sense in taking all of 
the 1l()(les." Dctt'rmined to makcsound 
dccisions about her own treatmcnt, she 
went to work learning all shecoldd ahout 
hl'fllisease. " I ... \~.lIltcd to know what m)' 
options were." says \Veller, a de\"Clopment 
officer for [he University of Missouri-
Rolla. " I wanted to know the why. I 
wantl'{\ to know all the statbtics of what 
my chances uf recurrence were going to be. 
\Vllat my long-term survivahility would 
be. Inet-'(Ied more information than Illy sur-
" 
STORY BEA H LER 
As medical dirtc/Qru[ MU'J ElfiJ Fischel 
eWlCer Utl/cr, David Ow offirs IJlIlimts lifl-
slwillg o.1:.erilllenud t1"l'mmelltsjor Clmar. 
b'Con was willing or prepared to give me, so 
1 sought out a d ifferent level of care." 
Her Internet research led her to II 
national study under way at select cancer 
eenters around the country. The study is 
evaluating an experimental treatment 
called sentillel n{l(le hiopsy. \Vith this 
technique, su rgeons use a dye or a radioac-
tive marker to identify a primary lymph 
node that drains the breast CD.ncer. They 
remove onl), that node , or just a few oth-
ers, and put the tissue through a battery 
of lab tests searching for the tiniest evi-
(Ience of tumor cells. Early stmly results 
suggest that if the sentinel n()(le is free of 
discase there's an overwhelming likeli_ 
HllWI 
hood that breast cancer has not spread to 
other lymph nodes. If the test is positive, 
it g ives doctors more infornlation about 
treating individual cases with additional 
surgery or with radiation and drugs. 
\\feller made another important discov-
ery on the Internet. MU's Ellis Fischel 
Cancer Center, 90 miles up Highway 63 
in Columbia, is one of just a few dozen 
hospitnls involved in the sentinel node 
study. A family friend put her in touch 
with canccr surgeon Davi(l Ota, who is 
medical director of Ell is Fischel. 
The next day she wassiuing in Ota's 
office as he described the new techni(lue 
and enrolled ber in the study. Since then , 
wdler has had the sentinel node surgery 
followed by radiation therapy and is taking 
part in two additional research studies. 
Thousands of Missourians have discov-
ered that same high le\"C1 of care ever 
since Ellis Fischel first opened its doors in 
19"0. Back then, the state_run hospital 
treated cancer patient!! who were too 
poor to pay for me(l ieal care. 
One in three Americans w ill develop 
cancer during their lifetime. Specialisu 
like Ota are optimistic about the 
proopects for curing cancer one day. 
'" \Ve' re making important strides," Ota 
says. "Cure rates arc going up. There are 
better screening and early deteClion pro_ 
grams. \\l! 're de\"Cloping more effective 
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treatments. The pil>cline is full of new 
drugs that will comc out in the next few 
years. nut WI' still need better tools." 
That's why MU is taking the next big 
step to elevate its cancer resea rch and 
trcatnlent program . Mizzou has launched 
an initiative that will build Ellis FisclU'1 
and the Uni \'ers it y into a comprehensh'e 
cancer center, as deSignated by the 
National Cancer Inst itute. Scientists and 
(Ioctors all o\"Cr campus arc joining the 
effort, but it 's 11 big job. 
The National Cancer Institute has 
awarded this prestigious ranking to only 
34 institutions aroUlJ(1 the country dUlt 
demonstrate excellcnce in both basic can· 
ce rresearch and in clinicaitreatmcnt. 
There arc no comprehensive canccr cen-
ters in Missouri or in the snrroulUling 
s tates of Iowa, Arkansas or Kansas. 
" The comprehensive Cllncer center (II'S-
ignation puts Iln institution in a class w ith 
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\"Cry few others," says Daniel \Vinship, 
MU's vice clumcellor for health affairs. " It 
rcally is the highest level of achievement 
that can be recogni7.ed in the whole area of 
canccr research, education and care." 
Hut the deSignation carries more than 
prestige, \Vinship explains. "You have a 
leg up on your ability to have grallt pro. 
posals accepted. 0 11 your ability to be 
included in cancer protocol studies 
t hroughout the nation. You' re in a posi-
tion to participate in ways that you ne\"Cr 
were before." It also will help MU 
recruit thc country's finest cancer doctors 
and researchers. 
Achieving that deSignation w ill requ ire 
Mizzou to invest millions of dollars in peo· 
pic and in bricks·and.mortar infranruc· 
ture. That investment, though , w ill ),ield 
huge rNurns in public and private finanI" 
ing ami ill impro\'Cd cancer care. In the 
process, MU will be training a new cadre 
mOl 
ofcanccr professionals to treat patienLS 
around the state and the country. 
EYcr),comprel,ensi\'eeancereenter 
must ha\'e a major cancer research focus, 
not just a researcher here and there. ·' YO\I 
need a critical mass of people w ho arc car· 
rying out resea rch in a varicty of areas." 
\Vinship sa),s. MU must also demonstrate 
an institutional commitment, substantial 
interdisc iplinary collaboration and out. 
reach efforts arouml the area. 
"A ll of these things we have," Winship 
sa),s. " \\le can poi nt and say we have all of 
those pieces, but ever)' one of them needs 
to be enlarged . expande(1 and refined, and 
(Ie,,"eloped further in order to get us over 
this threshold ." Currently, the Uni\'ersit), 
is look ing to a number of sources for fund . 
ing, including state and federal grants and 
private donations. Cancc r resea rch will 
become one of the priorit ies of t he campus 
mission enh anccment program . 
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The costs will he great . but so will the entire enterprise. Cancer specialists there 
be ncflts. when the latest resea rch at 1\1 U are involved in more than a hundred 
ond other universities becomes ovoilable to 
doctors w ho ore treotingcanccr patients. 
A key componelll uf the comprehensive 
eoncer centl'f (Iesignation is what's called 
" translational research :' or. as Ota 
describes it . " mOUSC·tO·lllall research" in 
whicll knowledge gained in the lahorotory 
is pili (0 usc ot 0 patient 's bedside. 
A numhe r of importolll resources help 
MU mnkc nni(lue contributions to cancer 
rescarch . Radiation isone of the most 
important tools to treat the disease, ami 
Mizzou 's Reseorch Reactor is the most 
powerful reactor at allY nniversity in the 
country. The reactor pro<luces ra(lioaceive 
isotopes used in new medicines to tarbrct 
and kill cancer cclls. It 's the only reactor 
in the country to produce an isotope of a 
rare element cal1e(1 samarium , which a 
team of 1\1U researchers used to invent a 
new drug called ~lIldramet. 
The drug is almost a miracle for thou. 
sands of pc<Iplc w ho suffer the crushing 
paiu of bone cancer. After one injection 
some patients live relatively pain. free for 
as long as a year. 
Sc ielilis ts ot Mizzou hove been respon. 
s ible for developing other drugs like 
~Iadromet which, because t hey contain 
radioactive isotopes, arc known as radio· 
pharmoceUl icols. Another drug under 
de"elopmellt uses microscopic ccromic 
spheres to ca rry cancer. killing racliotion 
thot attacks tumors in the liver, M U's 
reactor is one of the few able to produce 
radioactive isotopes thot decay very 
qUickly. That 'scrucial for the drug to do 
its work on concer cells and thell leove the 
body before it domagcs healthy tissue. 
\\'hell it comes to basic life sciences 
reseorch that helps unlock the mysteries 
of callcer, MU is in a good position os one 
of a handful of universities that are home 
to both a medical school and a college of 
veterinary me(licine. Strong basic 
research programs exist across campus in 
genet ics, medical informatics, cell hiology 
ami nutri t ion , among others. E llis Hschel 
Cancer Cellter is the cornerstone of the 
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experimental treatments, and lhat num· 
her will g row if it hecomes a comprehen. 
s i\'ecancer cellter. 
Jeffrey Bloss is olle of a handful of doc· 
tors oround the country testing a novel 
new theropy that shows remorkable 
promise for treating ovarian cancer. Right 
now, o\'ariall callcer is one of the most dif. 
ficult to treat. The tumor responds "veil to 
initial surgery and chemotherapy, but the 
cancer oftcn reappears within a year and 
kills neorly half the women who at first 
appeared to be cured. Bloss, director and 
associate professor of gynecologic oncol· 
ogy, is taking on the prohlem with a new 
drug called Ovarex. Unlike tra(litional 
chemotherapy, this drug docsn ' t kill 
(umorcells with I>oison ; ralher it helps 
the immulle system fight off the invader, 
As scientists learll more ond more 
about tumors, t hey can turn that knowl· 
edge into a weapon. " For years there were 
three woys thot you could address a call, 
cer," Bloss says. " You could poison it with 
a (Irug, you coul(1 kill it with energy-
ra(liation or a laser heam- or you coul(1 
cut it out with surgery. Now, we've taken 
it one stcp further and we're asking 
' \\~ II , what caused it?\Vhat can we do to 
the actual mechanism of the celt to make 
it revert back to normal?' Because cancer 
isn ' t something you inhale-it 's olle of 
your cells that 's gone haywire, and we 
want to get it back on track." 
One of the ways scientists like Bloss 
clln get those cancerous cells back on track 
is through 0 hasic understanding of how 
heolthy cells function . For instance, they 
kllOw that nearly every cell in the body 
contains Il tumor suppressor gene called 
PH. It 's something like a cell policeman. 
The gene helps cells grow normally, do the 
work they' re supposed to do and then die 
of old age, This tumor suppressor !;Cne also 
patrols the cell looking for growth abnor· 
molities, such ascancer.eausing mutations. 
\Vhen it finds them, the normol P53 gene 
causes a cell to commit suicide. 
Some cancers, particu1arly ovarian Call' 
~1l101 
A hllmullhlliYtluurjlthutmicrt)scolJiC 
ctmmic lphu·tl. uhich IJacli a prtcill onto 
two pl/nch of rnJiol,hanliactlllicall for 
Irfalillgli~rcallctr. 
cer, arc caused by (Iefcets in these cellular 
policemen. " The gene geu damaged , so 
those cells ill the ovary without that gene 
grow uncontrolled," Bloss says. "They no 
longer function normally and they don' t 
eyer (lie, they just keep grow ing and grow. 
ing. That 's the definition of cancer-
uncontrolled growth that just won't stop." 
At Ellis Fischel, 13I0ss and his col· 
leagues arc testing a new therapy to rein. 
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tro<luce the P53 gene into cancer patients. 
The gene is biochemically "glued " to a 
harmless virus, which carries this gene 
into cancer cells. " \Vhat we're doing is 
putting the genetic blueprint back into 
thecell, " lUosssays. "\\'hat we've seen, 
both in the laboratory and now in humans 
as well, is that the cell reverts back to 
normal and the cancer goes away," 
Experimental results ha\'C been dra' 
matic, but he cautions that the therapy is 
too new to draw hard,and,fast conelu, 
S iOIlS, Although earlier studies show this 
gene therapy shrinks tumors in humans, 
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nloss says, " \Ve're now in the process of 
learning how well it works and for how 
long. \viII the p:nient Slay cancer· free, or 
will the cancer come back when you quit 
giving the produce" 
The explosion of knowledh>'C about 
human genetics is another bright spot in 
the fight against cancer. Because all can-
cers invoke some genetic abnormality, 
learning more about how genetic defects 
cause cancer could prOVide answcrs. As a 
pathologis t at Ellis Fischel , Charles 
Caldwell has spent decades studying the 
impact of those genetic abnormalities in 
cancers. In recent years he's had imrlOr, 
tant new tools at his disposal- high, 
speed computers that analyze data in a 
fra ction of the time that it used to take. 
This new field is called bioiuformatics. 
Onc giant step is a new research tech-
nique called microarray technology, 
which allows researchers to compare tcns 
of thousands of DNA sequences simulta-
neously. " It allows us to hunt across all 
the genes that exist in a l>erson and iden_ 
tify abnormalities in a tumor virus \'s. 
normal DNA," Caldwell says. That tech-
nology would let researchers determine 
who might be more susceptible to certain 
cancers and other diseases. It could help 
to dctcrmine what kinds of chemotherapy 
might ... vork best on a tumor, or, it could 
help find a genetic switch to turn off 
tumors. Microarray technology might 
evcn answer ljuestions about why the 
same type of tumor grows more npidly in 
some people than in others. 
Caldwell is another Ellis FISchel physi-
cian who has experienccd the synergy that 
can exist between doctors and basic 
researchers arOlUld campus---the kind of 
syncrgy generated at a comprehcnsive can-
cer center. Caldwc ll has been working 
with computer engineers Jim Keller and 
Paul Oader to adapt " fuzzy logic" com_ 
puter tcchuology to cancer research. The 
U.S. military first develOP£d fuzzy logic to 
search for hidden laml mincs or scan satel-
lite photos looking fo r enemy tanks lurking 
behind trees, Caldwell is studying how to 
use the same technology to search for can, 
~lllOI 
cer cells hiding in human tissuc samplcs. 
A comprehensi .... e cancer center at MU 
would he a catalyst for more of these 
research interactions. " \Ve ha .... e people 
spread all o ... ·er campus who have interests 
that right now aren't necessarily focused 
on cancer, but they might." Caldwcll says, 
" Right 110W they' re looking at cell biology 
or gene control or somcthing clse, but 
they're starting to think along the lincs of 
evol\'ing their research toward cancer. 
"You know, computcr engineerl!' are 
good programmers, but they don't know 
what problems need to be solved in can-
cer. The canccr people know the problems 
they havc. but they don't know what 
tools are availahle to apply to those prob-
lems. If you bring these people together, 
they sort of elick. " 
That synergy is evident among scien-
tists in diSCiplines that span the campus. 
As MU huilds its programs toward a 
nationally recognized comprehensive can-
ce r center, research produced in uni .... cr-
s it y laboratories can go to work helping 
more cancer patients like Anne \Veller 
with inno .... ath·e treatments. 
And \Vcller 's experience had an impact 
on her co' workers, " It encouraged some of 
the younger women in my officc to gct 
their annual mammogram. It 's kind of a 
tough way to be a role modcl, but I can 't 
stress that enough. You ncc<1 to go for 
those exanu, along with self-examination 
and routine medical care." 
The core \Veller received at Ellis 
Fischel made all the diffcrcnce in her 
treatment. "At Ellis Fischel. everyone you 
deal w ith is .... c ry sensiti .... e [0 w hy you 're 
being treated there," \\'cller says. " It ·s a 
time in your life when you 're facing your 
mortalit y, You're asking yourself, ' Am I 
going to have a future? \\!h.nt am I going to 
do for nly children?' So many things are 
pass ing through your mimi. 
"Umil you need thcm. I guess the ordi, 
nary person doesn't think too much about 
the ser .... ices that are co .... e red at a cancer 
center," \\'eller says. " It really docs make 
a differcnce to be able to go to a place 
w hcre all they do is treat cancer," • 
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